Protalix Biotherapeutics, Inc. quarterly report, Q2 FY2003

Business Context and Reporting Period

This Form 10-QSB covers the quarterly period ended June 30, 2003, for Orthodontix, Inc. (Note: The request metadata listed "Protalix Biotherapeutics, Inc.", but the filing text explicitly identifies the issuer as Orthodontix, Inc.). The Company is a shell entity with no current operating revenues, devoting its resources to seeking a merger or acquisition with an operating business. It has evaluated targets in aircraft maintenance, health care, pharmaceuticals, and financial services since July 2001.

Key Financial Metrics

Metric Q2 2003 (3 Months) YTD 2003 (6 Months) YTD 2002 (6 Months)
Revenue $0 $0 $0
Net Loss $(29,784) $(62,271) $(67,934)
Loss Per Share (Basic/Diluted) $(0.01) $(0.02) $(0.02)
Cash and Cash Equivalents (End of Period) $776,581 $776,581 $837,798
Total Liabilities $61,707 $61,707 $79,074
Net Cash Used in Operating Activities N/A $(91,939) $(97,604)

Outstanding Shares: 2,915,428 common shares as of August 5, 2003.

Material Changes vs. Prior Period

  • Net Loss Reduction: The net loss for the six months ended June 30, 2003, decreased to $62,271 from $67,934 in the same period in 2002. This improvement was driven by lower general and administrative expenses ($61,262 vs. $77,498) and a reduction in interest income ($3,241 vs. $9,252).
  • Asset Realization: The Company settled a note receivable of approximately $65,000 (outstanding at Dec 31, 2002) for $60,900 in cash, recording a one-time operating expense of $4,250. This resulted in a net cash inflow from investing activities of $60,881 for the six-month period.
  • Liquidity: Cash balances decreased by approximately $31,000 during the six-month period, primarily due to operating cash burn, partially offset by the collection of the note receivable.

Outlook, Risks, and Management Commentary

  • Plan of Operation: Management intends to continue seeking a business combination. No contractual commitments exist for any acquisition. The Company plans to use common stock, cash, or other funding sources to effect a transaction.
  • Liquidity Outlook: Management believes current cash reserves ($776,581) are sufficient to cover operating expenses for at least the next twelve months.
  • Risks: There are no assurances that the Company will consummate a merger or acquisition in the near term, or on favorable terms. Even if a transaction occurs, there is no guarantee the combined entity will be profitable.
  • Controls: Management concluded that disclosure controls and procedures were effective as of June 30, 2003, with no significant changes in internal controls.

Investor Verification Checklist

  • Shell Status: Verify the Company has no operating revenue and relies entirely on interest income and potential acquisitions.
  • Cash Runway: Confirm the $776,581 cash balance is sufficient to sustain operations for the projected 12-month period without additional capital raises.
  • Acquisition Pipeline: Assess the likelihood of a merger given the lack of specific targets or binding agreements mentioned in the filing.
  • Share Count: Note the static share count of 2,915,428; any future acquisition may significantly dilute existing shareholders if stock is used as currency.